Retrospective Cohort Study
Copyright ©The Author(s) 2020 Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 14, 2020; 26(30): 4428-4441
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4428
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flowchart.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Cumulative remission rate of anti-tumor necrosis factor naïve patients to vedolizumab therapy (vs anti-tumor necrosis factor exposed patients, P < 0. 001).
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Cumulative loss of response of anti-tumor necrosis factor exposed patients to Vedolizumab therapy (vs anti-tumor necrosis factor naïve patients, P = 0. 011).
  • Citation: Pulusu SSR, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, Van Langenberg D, Thin L, Mogilevski T, De Cruz P, Radford-Smith G, Flanagan E, Bell S, Kashkooli S, Sparrow M, Ghaly S, Bampton P, Sawyer E, Connor S, Rizvi QUA, Andrews JM, Mahy G, Chivers P, Travis S, Lawrance IC. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol 2020; 26(30): 4428-4441
  • URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4428.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v26.i30.4428